MaxCyte, Inc. Filing of Form 8-K
29 January 2024 - 6:00PM
RNS Regulatory News
RNS Number : 1340B
MaxCyte, Inc.
29 January 2024
MaxCyte announces filing of
Form 8-K
ROCKVILLE, MD, January 29, 2024 - MaxCyte, Inc.,
(Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell-based therapeutics and innovative bioprocessing applications,
announces that it has filed a Form 8-K with the SEC announcing the
departure of Dr. Cenk Sumen as Chief Scientific Officer. Dr. Sumen
will maintain a relationship with the Company as a member of
MaxCyte's Scientific Advisory Board.
A copy of the Form 8-K is available
to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the
Company's website, https://investors.maxcyte.com/.
About
MaxCyte
At MaxCyte, we
pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years
honing our expertise by building best-in-class platforms,
perfecting the art of the transfection workflow, and venturing
beyond today's processes to innovate tomorrow's solutions. Our
ExPERT™ platform, which is based on our Flow Electroporation®
technology, has been designed to support the rapidly expanding cell
therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development
through commercialization of next-generation, cell-based medicines.
The ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology platform, as well as
scientific, technical and regulatory support, we aim to guide them
on their journey to transform human health. Learn more
at maxcyte.com and follow us on X (formerly Twitter) and
LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler,
CFA
|
+1 415-937-5400
ir@maxcyte.com
|
Nominated Adviser and Joint
Corporate Broker
Panmure Gordon
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886
2500
|
UK IR
Adviser
ICR
Consilium
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
UPDUWARRSAUAUUR
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024